Contact

Media
Andrew Clark
Genomic Health
+44 (0) 20 7300 6202
+44 (0) 7932 677184

andrew.clark@bm.com

Genomic Health's Oncotype DX® breast cancer test can significantly improve patient outcomes for node-positive patients, international studies reveal

- *15 featured abstracts at the 15th St Gallen International Breast Cancer Conference underscore the growing adoption of the company's cutting-edge genomic test to identify those patients who will benefit from chemotherapy after breast cancer surgery*

LONDON, United Kingdom, [March 20, 2017] – Genomic Health today announced the presentation of 15 abstracts for the Oncotype DX® breast cancer test at the 15th St Gallen International Breast Cancer Conference in Vienna, Austria. The test uses state-of-the-art genomic analysis techniques to uncover the unique footprint of each patient's tumour and generates a Recurrence Score® result which predicts the likelihood that the patient's cancer will return and whether chemotherapy is likely to provide benefit.

Extensive research has already shown clearly the benefit of the Oncotype DX test for lymph node-negative breast cancer patients, reducing the number of women undergoing unnecessary chemotherapy by up to 60 per cent.[1] However, international studies released at the St. Gallen International Breast Cancer Conference have revealed the significant impact Oncotype DX can have on clinical outcomes for patient with node-positive disease.

- An analysis based on the Surveillance, Epidemiology, and End Results (SEER) registry program of the National Cancer Institute (NCI) looked at breast cancer-specific survival (BCSS) in more than 6,700 patients. The results showed that five-year BCSS was excellent in patients with Recurrence Score results less than 18 and micro metastases, 1-3 positive nodes. Survival worsened with increasing number of lymph nodes involved and higher Recurrence Score results.[2] These findings in node positive disease were recently updated and published in *Breast Cancer Research and Treatment*.
- A systematic review was also conducted across seven international studies including more than 9,000 patients with node-positive disease. These studies consistently identified patients with a low number of positive nodes (1-3) and low Recurrence Score results who had good clinical outcomes.[3]
- A pooled analysis of seven international studies including a total of 385 patients with 1-3 positive lymph nodes showed that testing with Oncotype DX significantly impacted treatment

decisions (43% change on average), resulting in a net reduction in chemotherapy use, similar to that seen in studies of node-negative breast cancer.[4]

"These new findings, based on results from thousands of patients in the USA and Europe provide more evidence on the value of Oncotype DX in deciding whether chemotherapy is needed or not for women with both node negative and node positive breast cancer, said Prof. Ian Smith, Consultant Medical Oncologist, Professor of Cancer Medicine, Royal Marsden Hospital, London. "This genomic test has already spared thousands of patients from unnecessary chemotherapy and reduced healthcare costs worldwide."

About Oncotype DX

Oncotype DX is the only genomic test validated for its ability to predict the likelihood of chemotherapy benefit as well as risk of recurrence in early-stage breast cancer. Healthcare systems across Europe are recognising the value of the test, which is incorporated in all major international clinical guidelines. Following assessment and recommendation by NICE in 2013, the Oncotype DX test is now widely available to patients across the UK. In France, Oncotype DX is available through a funding mechanism for innovative diagnostics. Other European countries that reimburse the test include Switzerland, Ireland, Greece and Spain. To learn more about the Oncotype DX test, visit: www.OncotypeDX.co.uk

About Genomic Health

Genomic Health, Inc. is a world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 700,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in Redwood City, California with UK headquarters in London. For more information, please visit, www.GenomicHealth.co.uk and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

# # #

[1] Loncaster J et al., Eur J Surg Oncol 2017
[2] Shak S, P225, St. Gallen 2017

[3] Mamounas E., P226, St. Gallen 2017
[4] Braybrooke J, P203, St. Gallen 2017